

## ORIGINAL ARTICLE

# Serum Lipid Peroxidation And Leptin Levels In Male And Female Type 2 Diabetic Patients In Gorgan (South East Of Caspian Sea), Iran

MARJANI A \*, VEGHARI G \*\*, BADELEH MT \*\*\*

### ABSTRACT

**Background:** The aim of the present study was to determinate the possible relationship between serum leptin and lipid peroxidation in male and female type 2 diabetic patients in Gorgan, Iran.

**Methods:** The subjects consisted of fifty type 2 diabetic patients and fifty age and sex-matched control subjects. The concentration of leptin, malondialdehyde, lipid parameters and insulin were measured in all subjects. The results were evaluated by using Independent sample 't' test and Spearman's correlation coefficient test.

**Results:** Leptin was correlated with BMI (male:  $r=0.339$  and female:  $r=0.426$ ,  $p<0.05$ ) and malondialdehyde levels (male:  $r=0.124$  and female:  $r=0.271$ ,  $p<0.05$ ) in the type-2 diabetic patients. In the control subjects, only a correlation between leptin and BMI was found (male:  $r=0.165$ , female:  $r=0.037$ ,  $p<0.05$ ).

**Conclusions:** In the correlation analysis using leptin as the dependent variable, BMI was found to be the predictor of leptin in males and females. Increased lipid peroxidation and hyperleptinaemia may play a role in the beginning and development of type 2 diabetes mellitus in this area.

**Key Words:** Leptin, Lipid peroxidation, Type 2 diabetes mellitus, Gorgan

\*,\*\*Department of Biochemistry and Biophysics, Biochemistry and Metabolic Disorder Research Center, Golestan University of Medical Sciences.

\*\*\*Department of Anesthesia, Golestan University of Medical Sciences.

**Corresponding Author:**

Abdoljalal Marjani, Gorgan Faculty of Medicine, Department of Biochemistry and Biophysics, Biochemistry and Metabolic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Golestan province, .Iran.  
Tel & Fax: +98(171)4421651 & 4440225  
E-mail:abdoljalal@yahoo.com

### Introduction

Diabetes is a major public health problem that is approaching epidemic proportions globally. This metabolic disease is one of the most common endocrine disorders affecting almost 6% of the world's population [1]. The prevalence of type 2 Diabetes mellitus (DM) ranges from 1.2% to 14.6% in Asia, 4.6% to 40% in the Middle East and 1.3% to 14.5 % in Iran [2],[3]. Diabetes mellitus is considered to be one of a rank of free radical diseases. It

causes complications, with increased free radical formation [4]. The process of lipid peroxidation is one of the oxidative conversions of polyunsaturated fatty acids to products known as malondialdehyde (MDA). MDA is a highly toxic molecule and its secondary products such as thiobarbutiric acid reactive substance (TBARS), are commonly used to evaluate lipid peroxidation [5]. A major development in energy balance regulation came with the discovery in 1994, of leptin, the protein product of the *ob* gene [6]. The functions attributed to leptin are extensive, including the regulation of food intake and energy balance through central hypothalamic pathways, its role as a major signal to the reproductive system in the inhibition of insulin secretion by pancreatic-cells and in the stimulation of glucose transport [7]. Previous studies of leptin in type 2 diabetes have shown no difference in basal levels, apart from expected differences due to BMI [8],[9] or a reduced leptin level, which may be

explained by differences in fat distribution [10]. Importantly however, the relationship between leptin and variables involved in glucose homeostasis and diabetes might show ethnic differences. A recent population study of Peruvian Indians compared with a Caucasian population showed that the Indians had higher insulin and lower leptin levels than the Caucasians [11]. Similarly, Chilean Indians also had higher insulin and lower leptin levels than the Caucasians [12]. Furthermore, Mexican American subjects showed higher levels of leptin as compared to age and sex-matched non-Hispanic whites [13]. These results observed in different ethnic groups reinforce that studies have to be undertaken in different populations. Thus, the aim of the present study was to investigate the possible relationship between serum leptin and the lipid peroxidation of male and female patients diagnosed with type 2 diabetes mellitus in Gorgan,Iran.

### **Materials And Methods**

This study was performed in the Biochemistry and Metabolic Disorder Research Center of Gorgan, Iran, in 2008. We had a study group including 50 patients of type-2 diabetes mellitus who referred to the Department of Diabetes Center in 5<sup>th</sup> Azar Hospital in Golestan University of Medical Sciences and 50 age and sex matched healthy control subjects. At the point of entry into the study, all diabetic patients underwent clinical and biochemical investigations. The data were collected by trained interviewers. The exclusion criterion was the coexistence of any other serious illness. Type-2 diabetes mellitus was defined as nonketosis diabetes by medical history and it is currently treated with oral agents. None of the patients had micro vascular complications (diabetic nephropathy or retinopathy). Administration of insulin for glycaemic control was considered to be an exclusion criterion. In the controls, diabetes was excluded by the fasting blood glucose test. Ten ml of fasting blood was collected from each subject by veinpuncture. The samples were

centrifuged for 10 minutes at 3000rpm. The serum was used for the analyses of malondialdehyde [14], fasting blood sugar [15], lipid profile (total cholesterol [16] including the analysis of triglycerides [17], HDL-cholesterol [18] VLDL-cholesterol and LDL cholesterol [19] in those who had type-2 diabetes mellitus and in controls. Lipids levels were measured by biochemical kits and Lipid peroxidation (the level of lipid peroxidation expressed as malondialdehyde [MDA]) was determined using previously described methods and spectrophotometry techniques (Model JENWAY 6105 UV / VIS ) in the Biochemistry and Metabolic Disorder Research Center (Faculty of Medicine). The results were reported as mean± SD. The statistical analysis was done with SPSS version -11.5 software. The results were evaluated by using Independent sample 't' test and Spearman's correlation coefficient test. P values < 0.05 were considered to be statistically significant.

### **The Measurement Of Serum Leptin**

Serum leptin levels were measured using a human leptin ELISA test kit (Biovendor, Research and Diagnostic Products, Czech).

### **The Measurement Of Serum Insulin**

Serum insulin levels were measured using a human insulin ELISA test kit (DiaPlus, Immunoenzymometric assay, USA).

### **The Measurement Of Serum Malondialdehyde**

2.5 ml of trichloroacetic acid was added to 0.5 ml serum and the tube was left to stand for 10 min at room temperature. After centrifugation at 3500 rev. / min for 10 min, the supernatant was decanted and the precipitate was washed once with sulfuric acid. Then, 2.5 ml of sulfuric acid and 3 ml of thiobarbituric acid (TBA) in sodium sulfate were added to this precipitate and the coupling of lipid peroxide with TBA was carried out by heating this mixture in a boiling water bath for 30 min. After cooling in cold water, the resulting

chromogen was extracted with 4 ml of n-butyl alcohol by vigorous shaking. Separation of the organic phase was facilitated by centrifugation at 3000 rev./min for 10 min and its absorbance was determined at awavelength of 530 nm.

## Results

The clinical characteristics of the type-2 diabetic patients and control subjects are described in [Table/Fig 1]. The mean duration of diabetes mellitus in type-2 diabetes mellitus patients was 1.5 years (range 1-3 years). The mean age of male and female patients in the type-2 diabetic and control subjects were 50.38±10.78 (18 males) and 50.46±9.53 (32 females), and 48.40± 10.49 years (20 females) and 48.46± 10.65 years (30 females), respectively. A number of obvious differences were found between the two subjects. The female type 2 diabetes mellitus patients had higher levels of fasting blood sugar, total cholesterol, LDL-cholesterol, HDL-cholesterol, VLDL-cholesterol, triglycerides, malondialdehyde, leptin and insulin as compared to the male subjects. Notably, the BMI (32.88±5.82 kg/m<sup>2</sup>), malondialdehyde (2.57±1.38 nmol/ml) and leptin levels (34.99±10.19 ng/ml) were significantly higher in female type-2 diabetes mellitus patients than in diabetic male subjects (25.05±1.85 kg/m<sup>2</sup>, 2.10±0.67 nmol/ml and 11.04±7.76 ng/ml,) (P< 0.05) [Table/Fig 1]. The data shown in Table 1 reveals that the BMI (30.60±5.50 kg/m<sup>2</sup>) and leptin levels (26.34±12.02 ng/ml) was significantly higher in female control subjects than in male subjects (25.97±4.36 kg/m<sup>2</sup> and 11.26±5.46 ng/ml,) (P< 0.05). There was no significant difference in other parameters in female type-2 diabetes mellitus patients and male subjects. The data of [Table/Fig 1]shows that the levels of fasting blood sugar, total cholesterol, LDL-cholesterol, VLDL-cholesterol, triglycerides, malondialdehyde and insulin were significantly higher in male and female (leptin was also higher) type-2 diabetes mellitus patients than in male and female controls (P< 0.05). But this is not the same for HDL-cholesterol, age and

BMI in female type-2 diabetes mellitus patients[Table/Fig 1]. There were no significant differences in age, BMI, HDL-cholesterol and leptin in male type-2 diabetes mellitus patients and in male control subjects. Leptin correlated positively and significantly with the BMI of diabetic and control males (r=0.339 and r=0.165, p<0.05) and females (r=0.426 and r=0.037, p<0.05). Leptin also correlated positively and significantly with malondialdehyde (MDA) in the male and female type-2 diabetes mellitus patients (r= 0.124, r= 0.271, p<0.05) [Table/Fig 2].

(Table/Fig 1) Comparison of Fast blood sugar, Lipid profile, Malondialdehyde, Leptin and Insulin between males and females group of type-2 diabetes mellitus patients and control subjects

Parameters	Males (type-2 diabetes mellitus patients) (n=18)	Males (control groups) (n=20)	Females (type-2 diabetes mellitus patients) (n=32)	Females (control groups) (n=30)
	Mean±SD	Mean±SD	Mean±SD	Mean±SD
Age (years)	50.38±10.78	48.80±10.49	50.46±9.53	48.46±10.65
Body Mass Index (kg/m <sup>2</sup> )	25.05±1.85 <sup>1</sup>	25.97±4.36 <sup>2</sup>	32.88±5.82	30.60±5.50
Duration of disease (years)	1.88±1.18	-	1.64±1.16	-
Fasting Blood Sugar (mg/dl)	164.33±63.56 <sup>4</sup>	89.40±6.45	183.64±94.30 <sup>3</sup>	88.20±8.27
Total cholesterol (mg/dl)	254.66±81.74 <sup>4</sup>	159.85±23.89	271.00±88.86 <sup>3</sup>	160.40±27.40
LDL-cholesterol (mg/dl)	169.50±85.86 <sup>4</sup>	98.50±25.77	208.70±74.49 <sup>3</sup>	101.74±23.11
HDL-cholesterol (mg/dl)	44.44±11.65	46.75±7.48	48.90±11.26	45.06±7.28
VLDLcholesterol (mg/dl)	33.96±15.85 <sup>4</sup>	22.14±7.03	34.45±18.45 <sup>3</sup>	20.83±8.85
Triglyceride(mg/dl)	169.83±79.28 <sup>4</sup>	110.70±35.17	173.40±94.09 <sup>3</sup>	104.16±44.28
Malondialdehyde (nmol/ml)	2.10±0.67 <sup>1,4</sup>	1.14±0.37	2.57±1.38 <sup>3</sup>	1.07±0.39
Leptin (ng/ml)	11.04±7.76 <sup>1</sup>	11.26±5.46 <sup>2</sup>	34.99±10.19 <sup>3</sup>	26.34±12.02
Insulin (µU/ml)	10.40±9.31	4.31±3.09	12.68±9.46 <sup>3</sup>	4.24±1.84

<sup>1</sup>p< 0.05 compared between diabetic males and females, statistically significant.  
<sup>2</sup>p< 0.05 compared between control males and females, statistically significant.  
<sup>3</sup>p< 0.05 compared between diabetic females and control females, statistically significant.  
<sup>4</sup>p< 0.05 compared between diabetic males and control males, statistically significant.

(Table /Fig 2) Correlations of leptin levels with biochemical parameters in type 2 diabetes mellitus patients and control subjects

	Leptin			
	Male		Female	
	Diabetic	Control	Diabetic	Control
Age (years)	-	-0.208	-0.054	0.137
BMI (kg/m <sup>2</sup> )	<b>0.339*</b>	<b>0.165*</b>	<b>0.426*</b>	<b>0.037*</b>
Duration (years)	0.165	-	0.394	-
FBS (mg/dl)	0.082	-0.063	-0.193	0.058
TC (mg/dl)	-	0.186	-0.204	-0.305
LDL-C (mg/dl)	0.071	0.059	0.066	0.005
HDL-C (mg/dl)	-	-0.119	0.033	-0.385
VLDL-C (mg/dl)	0.323	-0.104	-0.183	-0.233
TG (mg/dl)	0.363	-0.104	-0.017	-0.233
Insulin (µU/ml)	0.220	-0.242	0.041	0.339
MDA (nmol/ml)	<b>0.124*</b>	0.219	<b>0.271*</b>	-0.304

\*P<0.05, statistically significant.

## Discussion

In the present study, we have observed that the levels of malondialdehyde (MDA), a lipid peroxidation product and a marker

of oxidative stress, is increased significantly in male as well as in female diabetic patients [Table/Fig 1]. This apparently shows that diabetic patients are exposed to an increased oxidative stress via lipid peroxidation. Some other researchers have also reported elevated lipid peroxidation products in the blood samples of type 2 diabetic patients [20],[21]. Several studies have shown that lipid peroxidation is increased in diabetes, particularly in type 2 diabetes mellitus [22],[23],[24]. Jain [25] demonstrated that hyperglycaemia stimulates the lipid peroxidation of RBC and Kannan and Jain [26] later showed that it increases oxidative stress in cells in vitro. Contrary to our observations and to that of others, there are several studies which did not find increased oxidative stress in type 2 diabetes mellitus patients [27].

In an animal study, Midaoui and Champlain [28] suffered the rat from type 2 diabetes mellitus and examined oxidative stress in the model of rat. Notably, they observed that hyperglycaemia alone does not induce oxidative stress unless it was accompanied by insulin resistance; thereby, implying that the involvement of reactive oxygen species is selectively related to insulin resistance [29].

Our results reveal a significant increase in the concentration of MDA in type 2 diabetic patients as compared to the control subjects [Table/Fig 1]. This is in agreement with the other published reports [22],[23],[24],[25],[26]. Our results show that BMI, MDA and leptin are statistically increased in female diabetic patients as compared to male subjects [Table/Fig 1].

Many investigators have demonstrated that leptin has a major relationship with BMI [30],[31],[32],[33],[34],[35]. In our study, also, leptin showed a correlation with BMI, both in males and females with diabetes and in control subjects. Leptin showed a correlation with MDA in both males and females with diabetes. A clear tendency towards being obese and overweight was apparent in female and male diabetic patients (BMI,  $30.07 \pm 6.08$  and  $25.05 \pm 1.85$

$\text{kg/m}^2$ ) and in control subjects (BMI,  $30.60 \pm 5.50$  and  $25.97 \pm 4.36$   $\text{kg/m}^2$ ). Some of the type 2 diabetes mellitus patients suffered from Hyperlipidaemia. Therefore, our results apparently showed that being obese and overweight gave rise to increased oxidative stress in type 2 diabetes mellitus patients. Being obesity and overweight did not change the oxidative stress in the control subjects. Our study focussed on the association between serum leptin concentration and lipid peroxidation in type 2 diabetics. Recent studies have showed that leptin significantly increases intracellular reactive oxygen species in microvascular endothelial cells, particularly in diabetics [36]. According to our study, increased leptin levels observed in male and female diabetics may be related to increased lipid peroxidation [Table/Fig 2]. Literature findings on the role of leptin in diabetes is conflicting. Investigators have reported either increased [37], decreased [38],[37],[38],[39] or unchanged [40],[41] leptin levels in diabetics. As Wauters et al. [42] have pointed out, adiposity and gender are the main determinants of leptin levels in normal controls and diabetic patients. Therefore, part of the controversy among previous reports could be related to the difference in the adiposity or the gender of the patients. Many investigators have described leptin alterations only in obese or overweight patients [38], [37],[40]. Few workers have studied only men [37] or women [39]. The mechanism by which leptin stimulates oxidative stress conditions is unclear, but it may be related to the fact that leptin stimulates mitochondrial fatty acid oxidation and the increased generation of reactive radicals [43]. Sebnem et al. [44] have observed a significant decrease in the leptin levels in the plasma of streptozotocin- induced diabetic rats. Streptozotocin-induced hypoleptinaemia may be related to a reduced adipose tissue mass and to the reduced assimilation and storage of energy substrates in the fat tissue in insulin deficiency and/or to the direct toxic effect of streptozotocin on the adipose tissue [45]. Panarotto et al. [46] has described lower leptin concentrations in females with diabetes as compared to those in the

control subjects. Our data only appear to be in contrast with this finding; our patients actually had higher leptin levels and higher fasting serum glucose concentrations than those studied by Panarotto's group. Moreover, in correlation analysis, BMI is considered to be a significant predictor of hyperleptinaemia [Table/Fig 2]. In the correlation analysis using leptin as the dependent variable, BMI and MDA were found to be significant predictors of leptin. In the present study, it was found that there was a correlation between serum leptin and BMI in males and females in normal and diabetic subjects. Gender specific correlation showed an association between leptin and MDA in diabetic patients. Serum leptin showed a significant relationship to MDA in male and female diabetic patients ( $r = 0.124$  and  $r = 0.271$ ,  $p < 0.05$ ). This trend reflects the increased MDA in males and females. Therefore, serum MDA levels are confounded by leptin or *vice versa*, such that in diabetes. Nakanishi et al. [47] have investigated the association between leptin and oxidative stress and have explained this association exclusively through obesity. Many investigators demonstrated that leptin had a major correlation with BMI [48],[49],[50],[51],[52]. There is still a controversy that leptin concentrations are affected by type 2 diabetes. Surveys of Mexican-American [53] and German [54] subjects showed that leptin did not differ between normal subjects and subjects with type 2 diabetes, with matched BMI in males and females. In another report, it was found that baseline plasma leptin levels in subjects with newly diagnosed or long-standing type 2 diabetes were not significantly different from nondiabetic controls matched for BMI [54]. Other reports comparing plasma leptin levels between controls and weight-matched subjects with type 2 diabetes have led to discrepant conclusions, showing no effect [55],[56] or a decrease in leptin [57],[58]. Our present study shows a similar relationship between leptin and oxidative stress in obese and overweight type 2 diabetes mellitus hyperleptinaemic patients. Finally, our study on individuals who were referred to the Department of

Diabetes Center in 5<sup>th</sup> Azar Hospital in the Golestan University of Medical Sciences on the South East of the Caspian Sea indicated that Type 2 diabetes was associated with higher leptin and MDA levels and BMI. In the correlation analysis, we found a significant relation between leptin levels and BMI in males and females. Increased lipid peroxidation and hyperleptinaemia may play a role in the beginning and in the development of type 2 diabetes mellitus.

## References

- [1] Adeghate E, Schattner P, Dunn E. An update on the etiology and epidemiology of diabetes mellitus. *Ann N Y Acad Sci* 2006; 1084:1-29.
- [2] Azizi F, Guoya MM, Vazirian P, Dolatshahi P, Habbibian S. Screening for type 2 diabetes in the Iranian national programme: a preliminary report. *East Mediterr Health J* 2003; 9:1122-7.
- [3] Azizi F, Gouya MM, Vazirian P, Dolatshahi P, Habbibian S. The diabetes prevention and control programme of the Islamic Republic of Iran. *East Mediterr Health J* 2003; 9:1114-21.
- [4] Baynes JW. Role of oxidative stress in development of complications in diabetes. *Diabetes* 1991; 40:405-12.
- [5] Del Rio D, Stewart AJ, Pellegrini N A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. *Nutr Metab Cardiovasc Dis* 2005; 15:316-28.
- [6] Zhang Y, Proenca R., Maffei M., Barone M., Leopold L, and Friedman J M. (1994) Positional cloning of the mouse obese gene and its human homologue. *Nature (London)* 1994; 372:425-32
- [7] Wauters M, Considine RV & Van Gaal LF. Human leptin: from an adipocyte hormone to an endocrine mediator. *European Journal of Endocrinology* 2000; 143:293-311.
- [8] Tasaka Y, Yanagisawa K, Iwanoto Y: Human plasma leptin in obese subjects and diabetics. *Endocr J* 1997; 44: 671-76.

- [9] Jianmeil L, Hasan A, Samuel DJ: Basal and stimulated plasma leptin in diabetic subjects. *Obes Res* 1999; 7:537-44.
- [10] Van Gaal LF, Wauters MA, Mertens IL, et al: Clinical endocrinology of human leptin. *Int J Obes* 1999; 23: 29-36 (suppl 1).
- [11] Lindgärde F, Söderberg S, Olsson T, et al: Overweight is associated with lower serum leptin in Peruvian Indian than in Caucasian women. A dissociation contributing to low blood pressure? *Metabolism* 2001; 50:325-29.
- [12] Perez-Bravo F, Albala C, Sanotos JL, et al: Leptin levels distribution and ethnic background in two populations from Chile: Caucasian and Mapuche groups. *Int J Obes Relat Metab Disord* 1998; 22: 943-48.
- [13] Wei M, Stern MP, Haffner SM: Serum leptin in Mexican American and non-Hispanic association with body mass index and cigarette smoking. *Ann Epidemiol* 1997; 7:81-86.
- [14] Satoh K. Serum lipid peroxide in cerebrovascular disorders determined by new colorimetric method. *Clin. Chim. Acta.*1978; 90: 37-43.
- [15] Trinder P. Determination of blood glucose using 4-amino phenazone as oxygen acceptor..*Journal of Clinical Pathology* 1969; 22: 246.
- [16] Allain CC, Poon LS, Chan CS, Richmond W, Fu PC.1974. Enzymatic determination of total serum cholesterol. *Clinical Chemistry* 1974; 20: 470-5.
- [17] Bucolo G,David H.Quantative determination of serum triglycerides by the use of enzymes. *Clinical Chemistry* 1973; 19: 476-82.
- [18] Fruchart J.C., Rev. Fr. Des laboratoires 1982; 103:7.
- [19] Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem*1972;18: 499-502.
- [20] Maritim AC, Sanders RA, Watkins JB 3rd. Diabetes, oxidative stress, and antioxidants: a review. *J Biochem Mol Toxicol* 2003; 17:24-38.
- [21] Sundaram RK, Bhaskar A, Vijayalingam S, et al. Antioxidant status and lipid peroxidation in type II diabetes mellitus with and without complications. *Clin Sci (Lond)* 1996; 90:255-60.
- [22] Atli T., Keven K., Avci A., Kutlay S., Turkcaper N., Varli M., et al. Oxidative stress and antioxidant-status in elderly diabetes mellitus and glucose intolerance patients, *Arch. Gerontol. Geriatr.* 2004; 39: 269-75.
- [23] Marjani, A., Moradi, A., Saeedi, M. Plasma lipid peroxidation zinc and erythrocyte cu-zn superoxide dismutase enzyme activity in patients with type 2 diabetes mellitus in Gorgan City (South East of the Caspian Sea). *Journal of Medical Sciences.* 2007; 7: 585-90.
- [24] Maharjan BR, Jha JC, Adhikari D, Vishwanath P, Baxi J, Alurkar VM, Singh PP. A study of oxidative stress, antioxidant status and lipid profile in diabetic patient in the western region of Nepal. *Kathmandu University Medical Journal* 2008; 6:16-22.
- [25] Jain SK. Hyperglycemia can cause membrane lipid peroxidation and osmotic fragility in human red blood cells. *Am.Soc-Biochem and Mol Biol* 1989;213:40-5.
- [26] Kannan K, Jain SK. Effect of high glucose on cellular proliferation and Lipid peroxidation in cultured verbo cells. *Horm. Met.Res* 1994; 26:322-5.
- [27] Singh PP, Gupta S, Barjatiya MK, Mamtha GP, Adhikari D. Oxidant antioxidant dovetail hypothesis: Let us not sprint before we stand. In: *Free Radicals and Antioxidants in Health and Disease.* Udaipur,India. Eds and Pubs. Singh PP et al, Chaudhary Offset Print. 2007:1-31.
- [28] Midaoui AE, Champlain J. Effects of glucose and insulin on the development of oxidative stress and hypertension in animal models of type 1 and type 2 diabetes. *Journal of hypertension*; 2005; 23:581-8.
- [29] Houstis N, Evan D, Rosen, Lander ES. Reactive oxygen species have a causal role in multiple forms of

- insulin resistance. *Nature* 2006; 440:944-8.
- [30] Wei M, Stern HM, Haffner SM. Serum leptin levels in Mexican American and non-Hispanic whites: association with body mass index and cigarette smoking. *Ann Epidemiol* 1997; 7: 7- 80.
- [31] Vettor R, De Pergola G, et al . Gender differences in serum leptin in obese people: relationship with testosterone, body fat distribution and insulin sensitivity. *Eur J Clin Invest* 1997; 27: 1016 -24.
- [32] Tasaka Y, Yanagisawa K, Iwamoto Y. Human plasma leptin in obese subjects and diabetics. *Endocr J* 1997; 44: 671 -76.
- [33] Liuzzi A, Savia G, Tagliaferri M, et al. Serum leptin concentrations in moderate and severe obesity: relationship with clinical, anthropometric and metabolic factors. *Int J Obes Relat Metab Disord* 1999; 23: 1066- 73.
- [34] Gomez-Ambrosi J, Salvador J, Paramo JA, et al . Involvement of leptin in the association between percentage of body fat and cardiovascular risk factors. *Clin Biochem* 2002; 35: 315 - 20.
- [35] Bertin E, Rich N, Schneider N, et al . Insulin and body fat distribution have no direct effect on plasma leptin levels in obese Caucasian women with and without type 2 diabetes mellitus. *Diabetes Metab* 1998; 24: 229 - 34.
- [36] Yamagishi S., Amano S., Inagaki Y., Okamoto T., Takeuchi M., Inoue H. Pigment epithelium-derived factor inhibits leptin-induced angiogenesis by suppressing vascular endothelial growth factor gene expression through anti-oxidative properties. *Microvasc. Res.* 2003; 65: 186–90.
- [37] Al-Daghri N, Al-Rubean K, Bartlett WA, Al-Attas O, Jones AF, Kumar S: Serum leptin is elevated in Saudi Arabian patients with metabolic syndrome and coronary artery disease. *Diab Med* 2003; 20: 832–37.
- [38] Abdelgadir M, Elbagir M, Eltom M, Berne C, Ahren B: Reduced leptin concentrations in subjects with Type 2 diabetes mellitus in Sudan. *Metabolism* 2002; 51: 304–6.
- [39] Sayeed MA, Khan AKA, Mahtab HM, Ahsan KA, Banu A, Khanam PA, Ahren B: Leptin is reduced in lean subjects with Type 2 diabetes in Bangladesh. *Diab Care* 2000; 26: 547.
- [40] Haffner SM, Stern MP, Miethinen H, Wei M, Gingerich RL: Leptin concentrations in diabetic and nondiabetic Mexican-Americans. *Diabetes* 1996; 45: 822–24.
- [41] Snehalatha C, Ramachandran A, Satyavani K, Sivasankuri S, Vijay V: Difference in body fat percentage does not explain the gender dimorphism in leptin in Asian Indians. *J Assoc Physicians India* 1999; 47: 1164– 67.
- [42] Wauters M, Considine RV, Yudkin JS, Peiffer F, Deleeuw I, Van Gaal LF: Leptin levels in insulin resistance and insulin secretion. *Hormone Metab Res* 2003; 35: 92–96.
- [43] Yamagishi S., Edelstein D., Du X.L., Kaneda Y., Guzman M., Brownlee M. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase, *J. Biol. Chem.* 2001; 276: 25096–100.
- [44] Gulen S and Dincer S. Effects of leptin on oxidative stress in healthy and Streptozotocin-induced diabetic rats. *Mol Cell Biochem* 2007; 302:59–65.
- [45] Havel PJ, Uriu-Hare JY, Liu T, Stanhope KL, Stern JS, Keen CL, Ahren B Marked and rapid decreases of circulating leptin in streptozotocin diabetic rats: reversal by insulin. *Am J Physiol* 1998; 274:R1482–R1491
- [46] Panarotto D, Ardilouze JL, Tessier D & Maheux P. The degree of hyperinsulinemia and impaired glucose tolerance predicts plasma leptin concentrations in women only: a new exploratory paradigm. *Metabolism* 2000; 49: 1055-62.
- [47] Nakanishi S, Yamane K., Kamei N., Nojima H., Okubo M., Kohno N. A protective effect of adiponectin against oxidative stress in Japanese Americans: the association between

- adiponectin or leptin and urinary isoprostane, *Metabolism* 2005; 54:194–99.
- [48] Wei M, Stern HM, Haffner SM. Serum leptin levels in Mexican American and non-Hispanic whites: association with body mass index and cigarette smoking. *Ann Epidemiol* 1997; 7: 79- 80.
- [49] Liuzzi A, Savia G, Tagliaferri M, et al . Serum leptin concentrations in moderate and severe obesity: relationship with clinical, anthropometric and metabolic factors. *Int J Obes Relat Metab Disord* 1999; 23: 1066- 73.
- [50] Gomez-Ambrosi J, Salvador J, Paramo JA, et al . Involvement of leptin in the association between percentage of body fat and cardiovascular risk factors. *Clin Biochem* 2002; 35: 315 - 20.
- [51] Bertin E, Rich N, Schneider N, et al . Insulin and body fat distribution have no direct effect on plasma leptin levels in obese Caucasian women with and without type 2 diabetes mellitus. *Diabetes Metab* 1998; 24: 229 -34.
- [52] Hodge AM, Boyko EJ, de Courten M, et al . Leptin and other components of the metabolic syndrome in Mauritius\* a factor analysis. *Int J Obes Relat Metab Disord* 2001; 25: 126 -31.
- [53] McGregor GP, Desaga JF, Ehlenz K, Fischer A, Heese F, Hegele A, Lammer C, Peiser C, Lang RE. Radiomunological measurement of leptin in plasma of obese and diabetic human subjects. *Endocrinology* 1996; 137:1501–4.
- [54] Dagogo-Jack S, Liu J, Askari H, Tykodi G, Umamaheswaran I. Impaired leptin response to glucocorticoid as a chronic complication of diabetes. *J Diabetes Complications* 2000; 14:327–32.
- [55] Hattori A, Uemura K, Miura H, Ueda M, Tamaya N, Iwata F, Muraguchi M, Ohmoto Y, Iguchi A. Gender-related difference in relationship between insulin resistance and serum leptin level in Japanese type 2 diabetic and non-diabetic subjects. *Endocr J* 2000; 47:615–21.
- [56] Guler S, Cakir B, Demirbas B, Gursoy G, Serter R, Aral Y. Leptin concentrations are related to glycaemic control, but do not change with short-term oral antidiabetic therapy in female patients with type 2 diabetes mellitus. *Diabetes Obesity Metab* 2000; 2:313–16.
- [57] Abdelgadir M, Elbagir M, Eltom M, Berne C, Ahren B. Reduced leptin concentrations in subjects with type 2 diabetes mellitus in Sudan. *Metab Clin Exp* 2002; 51:304–6.
- [58] Roden M, Ludwig C, Nowotny P, Schneider B, Clodi M, Vierhapper H, Roden A, Waldhausl W. Relative hypoleptinemia in patients with type 1 and type 2 diabetes mellitus. *Int J Obesity Relat Metab Disord* 2000; 24:976–81.